Home › News › Tirzepatide Shortage Resolved, FDA Says, With New Compounder Guidance

Tirzepatide Shortage Resolved, FDA Says, With New Compounder Guidance

September 16, 2026 · 2 sources · 4 min read

Tirzepatide Compounding & Supply Safety & Regulation

Pharmacist with turban organizing shelves in a pharmacy, focused on healthcare. — FDA announcement that the tirzepatide shortage is resolved and compounder policies clarified — Photo: World Sikh Organization of Canada / Pexels

The US Food and Drug Administration has declared the tirzepatide shortage resolved and issued clarified policies for compounders as national GLP-1 supply stabilizes. Because compounding copies of a commercially available drug is generally permitted only while that drug is in shortage, the determination reaches directly into how many people currently obtain their medication.

The FDA has determined that the shortage of tirzepatide injection is resolved, ending a supply disruption that began in 2022 amid surging demand. The agency published the determination alongside clarified policies for compounding pharmacies and outsourcing facilities, whose legal authority to produce copies of a marketed drug is tied directly to that drug's shortage status.

The short version

The FDA determined that the shortage of tirzepatide injection, a GLP-1 and GIP receptor co-agonist, has been resolved after first being listed in 2022.
The agency paired the determination with clarified policies for compounding pharmacies and outsourcing facilities, published as GLP-1 supply nationally begins to stabilize.
Federal law generally allows compounders to make copies of an approved drug only while it is on the FDA's shortage list, so a resolution changes what compounders may lawfully produce.
Separately, Houston-based Centric Compounding recalled six lots of injectable products to the consumer level over elevated endotoxin levels in a glutathione active ingredient.
Anyone sourcing a compounded GLP-1 may want to confirm with their prescriber and pharmacy how the supply channel and product concentration will be handled going forward.

What did the FDA say about the tirzepatide shortage?

In a notice published to its drug alerts and statements page, the FDA said it has determined that the shortage of tirzepatide injection — a glucagon-like peptide-1 (GLP-1) medication — has been resolved. The agency noted that tirzepatide injection had been in shortage since 2022, driven by increased demand rather than a manufacturing failure. The notice was framed as a clarification of policies for compounders as national GLP-1 supply begins to stabilize.

Tirzepatide is the active ingredient in Eli Lilly's Mounjaro, approved for type 2 diabetes, and Zepbound, approved for chronic weight management. Pharmacologically it is a dual agonist: it activates both the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor, which distinguishes it from single-target GLP-1 drugs such as semaglutide. Demand for both indications climbed faster than supply through 2022 and 2023.

The FDA's determination is an administrative finding about availability, not a statement about the drug's safety or how well it works. It says the agency believes manufacturers can now meet national demand. That finding has legal consequences that fall almost entirely on a different group: the pharmacies and facilities that have been compounding their own versions of the molecule.

Why the FDA's shortage list governs compounded GLP-1s

Under the Federal Food, Drug, and Cosmetic Act, compounders operate in two categories. A 503A compounding pharmacy prepares individually prescribed medications for identified patients. A 503B outsourcing facility registers with the FDA, follows current good manufacturing practice requirements, and may produce batches without patient-specific prescriptions, typically for clinics and hospitals. Neither category's products are FDA-approved, and neither is reviewed for safety, effectiveness, or quality before reaching patients.

Both categories face a core restriction: they generally may not compound a drug that is essentially a copy of a commercially available approved product. The principal exception is when the approved drug appears on the FDA's shortage list. That exception is what allowed a large compounded tirzepatide market to develop from 2022 onward, supplying telehealth platforms, weight-management clinics and med spas across the country.

When the agency removes a drug from the shortage list, that exception narrows. This is why a supply determination that might otherwise read as bureaucratic housekeeping is, for a significant number of people, the most consequential GLP-1 news of the month. The FDA's notice explicitly addresses compounder policy rather than leaving the implications unstated.

If a switch between product formats changes the concentration you are working from, a tirzepatide dosage calculator is one way to check that what you record matches what your provider actually prescribed.

The FDA's recall notice lists the affected lots and the company contact information for anyone who believes they may have received one of the products. the FDA's recall notice.

What happens to compounded tirzepatide now

The practical question for anyone currently receiving a compounded version is what their provider and pharmacy do next. The FDA's notice is directed at compounders, and the agency has historically approached these transitions through its published policies rather than through immediate enforcement against every entity at once. Readers should expect the specifics — what a given pharmacy stops making, and when — to come from the pharmacy and prescriber, not from a general announcement.

It is worth being precise about what is and is not covered. The determination named tirzepatide injection. Other GLP-1 and incretin products have their own separate shortage histories and statuses, and nothing in the notice should be read as applying automatically to a different molecule. If you are tracking a non-tirzepatide protocol, the status of your specific drug is a separate lookup.

There is also a formulation dimension. Compounded preparations are frequently supplied as lyophilized powder requiring reconstitution, or as multi-dose vials at concentrations that do not match a manufacturer's pen. A move from a compounded vial to a commercially manufactured product generally changes both the delivery device and the arithmetic a person has been using to measure a dose.

Because recalls and supply transitions are both handled by lot and by refill date, inventory tracking is the record that turns a general announcement into a specific answer about your own vials.

A separate recall shows why compounded sourcing quality matters

The same week, the FDA published a recall notice from Centric Compounding of Houston, Texas. According to the announcement, the company is voluntarily recalling six lots of Glutathione 200 mg/mL, Myer's Cocktail and Tri-Immune Boost injectable vials to the consumer level. The stated reason is that the products were compounded using a glutathione active pharmaceutical ingredient found to contain elevated endotoxin levels.

Endotoxins are fragments of bacterial cell walls. They are not living organisms, which means a sterile-filtered product can still carry them, and they are not removed by the steps that eliminate viable bacteria. Injectable products are held to endotoxin limits for that reason. The recall was issued at the consumer level, meaning it reaches individual patients who may have vials in hand rather than stopping at distributors.

These are not GLP-1 products and the recall is unrelated to the tirzepatide determination. It is relevant here because it illustrates the same underlying point the shortage exception rests on: compounded injectables are not subject to pre-market FDA review, and their quality depends on the facility and on the raw ingredients that facility sources.

The FDA's recall notice lists the affected lots and the company contact information for anyone who believes they may have received one of the products.

Compounded products often arrive as lyophilized powder, and our guide to reconstituting peptides explains why the resulting concentration is not interchangeable with a manufacturer's prefilled device.

What is still unresolved

Several things the notice does not settle. It does not describe how long compounders have to wind down existing preparations, and it does not address personalized formulations that differ from the approved product — a category that has been contested between compounders and manufacturers throughout this period. Nor does it speak to pricing or insurance coverage, which is the reason many people moved to compounded sourcing in the first place.

It also leaves open how durable the supply picture is. The agency's language describes national GLP-1 supply as beginning to stabilize, which is a description of a trend rather than a guarantee. A shortage determination can be revisited if demand shifts again, though reinstatement is not something anyone should plan around.

Finally, the notice is a supply and policy document. Research on this drug class continues to move on a separate track, including work on dual and triple agonists, and none of that is affected by an availability finding.

According to the FDA's notice on compounder policies, the shortage of tirzepatide injection has been resolved after first being listed in 2022 due to increased demand.

What this means if you're tracking a protocol

If your current supply is compounded, the immediate practical step is a conversation with your prescribing provider and your pharmacy about what they intend to do, and on what timeline. Knowing your refill date and how much product you actually have on hand makes that conversation concrete rather than speculative, which is one of the more mundane arguments for keeping an accurate inventory record rather than estimating from memory.

If a transition to a commercially manufactured product does happen, the most likely tracking disruption is not the schedule but the measurement. A compounded vial at one concentration and a manufactured delivery device are not interchangeable in how a dose is read or recorded. Anyone who has been logging volumes in syringe units from a reconstituted vial will be recording something structurally different afterward, and it is worth deciding in advance how the log will reflect that break so historical entries remain interpretable.

On the recall: if you use compounded injectables of any kind, including products unrelated to GLP-1 therapy, the Centric announcement is a reminder that lot numbers are worth recording at the point you receive a vial. A recall is issued by lot, and a log that captures which lot went with which date is the difference between a clear answer and a guess.

Frequently asked questions

Does the FDA shortage resolution mean compounded tirzepatide becomes illegal immediately?

Not automatically or instantly for every entity. Federal law generally bars compounders from producing essential copies of a commercially available approved drug, with the shortage list as the main exception, so removing a drug from that list narrows what compounders may lawfully make. The specifics of timing and enforcement come from the FDA's published policies and from each pharmacy, not from a single announcement.You should ask your own pharmacy directly.

Is semaglutide affected by this tirzepatide determination?

No. The FDA's determination named tirzepatide injection specifically. Semaglutide and other incretin medications have their own separate shortage histories and current statuses on the FDA drug shortage database. Nothing in a tirzepatide supply finding transfers automatically to a different active ingredient, so anyone tracking a non-tirzepatide protocol needs to check that drug's own listing.

What is an endotoxin, and why did it trigger the Centric Compounding recall?

Endotoxins are fragments of bacterial cell wall that remain even after bacteria are killed or filtered out, which is why a product can be sterile and still exceed endotoxin limits. Centric Compounding said its glutathione active ingredient contained elevated endotoxin levels, prompting a voluntary consumer-level recall of six lots of glutathione, Myer's Cocktail and Tri-Immune Boost injectable vials.

What is the difference between a 503A pharmacy and a 503B outsourcing facility?

A 503A compounding pharmacy prepares medications against individual prescriptions for named patients. A 503B outsourcing facility registers with the FDA, must follow current good manufacturing practice requirements, and can produce batches without patient-specific prescriptions. Neither one's products are FDA-approved, and neither undergoes pre-market review for safety, effectiveness or quality.

Why was tirzepatide in shortage for so long?

The FDA said tirzepatide injection had been in shortage since 2022 because of increased demand. Tirzepatide is marketed as Mounjaro for type 2 diabetes and Zepbound for chronic weight management, and uptake across both indications outpaced available supply rather than resulting from a manufacturing defect or recall.

Sources

FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
U.S. Food and Drug Administration · September 16, 2026
Centric Compounding Issues Nationwide Recall of Glutathione, Myer's Cocktail, and Tri-Immune Boost Due to Elevated Endotoxin Levels
FDA MedWatch Safety Alerts · September 13, 2026

How this page is made. PeptideWiz News covers regulatory actions, published research, and industry developments from a fixed list of primary sources — the FDA, NIH, EMA, ClinicalTrials.gov, PubMed, peer-reviewed journals, and company press rooms. Articles are drafted with AI assistance from those sources, reviewed before publication, and always link to the original. Read the full editorial standards & corrections policy. This is journalism about peptides, not medical advice: it does not recommend any substance, does not state dosages, and is not a substitute for your provider.

← Back to all peptide news